GSK 携手前沿生物加速布局siRNA,中国企业研发实力正获国际认可GSK 重点合作布局小核酸,已具有多款重磅管线。据Insight 统计,自2009 年起,GSK 已进行多起小核酸相关BD 交易,其中较多集中于ASO 和siRNA 领域。ASO 领域,GSK 早期与Prosensa、Ionis、Aceragen 等企业合作,但其中与Prosensa合作的靶向DMD 靶点的管线已经停止开发、与...
Source LinkGSK 携手前沿生物加速布局siRNA,中国企业研发实力正获国际认可GSK 重点合作布局小核酸,已具有多款重磅管线。据Insight 统计,自2009 年起,GSK 已进行多起小核酸相关BD 交易,其中较多集中于ASO 和siRNA 领域。ASO 领域,GSK 早期与Prosensa、Ionis、Aceragen 等企业合作,但其中与Prosensa合作的靶向DMD 靶点的管线已经停止开发、与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.